Tivozanib hydrate (KRN-951; AV-951; KRN951; AV951; Fotivda), the hydrated form of tivozanib, is an orally bioavailable VEGFR (vascular endothelial growth factor receptors) inhibitor approved by European Medicines Agency (EMA) in August 2017 and US FDA in March 2021 for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). It inhibits VEGFR1/2/3 with IC50s of 30 nM/6.5 nM/15 nM, thus having antineoplastic activity.

纯度：≥98%

CAS：682745-40-0